Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, et al. No. 12-3824 (E. D. Pa.)

In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott’s branded drug, Doryx (delayed-release doxycycline hyclate).  The case alleges that Warner-Chilcott and its licensor, Mayne Pharmaceuticals, to forestall competition from less-expensive generic versions of Doryx, hatched an anticompetitive scheme that included last-minute changes to their product whose only real value was to delay generic competition, thereby violating § 2 of the Sherman Act.  The case alleges that Warner-Chilcott and Mayne’s scheme permitted them to charge Plaintiffs and members of the class artificially inflated prices for their purchases of delayed- release doxycycline hyclate.  Faruqi & Faruqi LLP was appointed co-lead counsel by the Court. The case ultimately settled for $15 million in late 2013.